Libo Pharma Corp. (TPEX:7888)
Taiwan · Delayed Price · Currency is TWD 28.90
-0.90 (-3.02%)
At close: Sep 2, 2026
Libo Pharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 642.01 | 801.03 | 275.42 | 75.26 |
Cash & Short-Term Investments | 642.01 | 801.03 | 275.42 | 75.26 |
Cash Growth | 90.14% | 190.83% | 265.95% | - |
Other Receivables | 1.82 | 1.59 | 0.54 | 0.56 |
Receivables | 1.82 | 1.59 | 0.54 | 0.56 |
Inventory | - | - | 1.74 | 2.02 |
Prepaid Expenses | 127.93 | 124.34 | 12.74 | 0.47 |
Other Current Assets | 0.26 | 0.02 | - | - |
Total Current Assets | 772.02 | 926.97 | 290.44 | 78.32 |
Property, Plant & Equipment | 2.15 | 2.84 | 3.71 | 3.4 |
Other Intangible Assets | 137.68 | 148.43 | 168.78 | 13.54 |
Other Long-Term Assets | 4.36 | 4.09 | 4.93 | 4.42 |
Total Assets | 916.21 | 1,082 | 467.87 | 99.67 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 0 | 0 | - | - |
Accrued Expenses | 17.76 | 18.66 | 6.19 | 7.17 |
Current Portion of Leases | 0.63 | 1.32 | 1.56 | 1.07 |
Other Current Liabilities | 1.8 | 1.48 | 0.45 | 0.35 |
Total Current Liabilities | 20.19 | 21.46 | 8.21 | 8.59 |
Long-Term Leases | - | - | 1.42 | 2.11 |
Total Liabilities | 20.19 | 21.46 | 9.62 | 10.7 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 752.35 | 752.35 | 409.23 | 265.03 |
Additional Paid-In Capital | 633.74 | 614.83 | 377.63 | 4.28 |
Retained Earnings | -480.06 | -296.3 | -318.61 | -171.33 |
Comprehensive Income & Other | -10.01 | -10.01 | -10.01 | -9.01 |
Shareholders' Equity | 896.02 | 1,061 | 458.24 | 88.98 |
Total Liabilities & Equity | 916.21 | 1,082 | 467.87 | 99.67 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 0.63 | 1.32 | 2.98 | 3.19 |
Net Cash (Debt) | 641.38 | 799.7 | 272.45 | 72.08 |
Net Cash Growth | 91.20% | 193.53% | 277.99% | - |
Net Cash Per Share | 8.61 | 12.79 | 5.82 | 2.72 |
Filing Date Shares Outstanding | 75.24 | 75.24 | 40.92 | 26.5 |
Total Common Shares Outstanding | 75.24 | 75.24 | 40.92 | 26.5 |
Working Capital | 751.83 | 905.51 | 282.24 | 69.73 |
Book Value Per Share | 11.91 | 14.10 | 11.20 | 3.36 |
Tangible Book Value | 758.35 | 912.45 | 289.47 | 75.44 |
Tangible Book Value Per Share | 10.08 | 12.13 | 7.07 | 2.85 |
Machinery | 3.99 | 3.83 | 2.82 | 9.33 |
Leasehold Improvements | 0.48 | 0.48 | 0.48 | 0.31 |